SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a massive surge driven by intense market speculation regarding new commercial partnerships in the AI optical interconnect space, further fueled by a significant short squeeze. The community is actively debating the sustainability of the company's valuation against its current revenue, while many are focused on the impact of potential institutional accumulation and the scarcity of available shares for shorting.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing intensified volatility as investors weigh a major workforce efficiency shift alongside broader software sector weakness, with market attention laser-focused on upcoming earnings for signals that AI infrastructure investments are successfully translating into Azure revenue growth.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is currently drawing significant community attention following the release of Phase 2/3 trial data for tovecimig, which met its primary efficacy endpoint in biliary tract cancer despite failing to reach statistical significance on the overall survival secondary endpoint. Investors are actively debating the company's robust balance sheet and regulatory pathway, weighing the clinical benefit against the uncertainty surrounding the study's crossover-confounded survival results.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

DRTS is gaining significant momentum as investors anticipate major catalysts, including an upcoming oral presentation of pancreatic cancer data at Digestive Disease Week and multiple ongoing clinical trial milestones. The community is actively discussing the company's progress in targeting difficult-to-treat solid tumors, with many viewing the current valuation as an accumulation opportunity ahead of potential data readouts.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending following the release of positive pivotal trial data for its in vivo CRISPR-based hereditary angioedema treatment, which has sparked significant debate regarding its commercial potential compared to existing therapies. While the community is actively discussing the validation of the company's gene-editing platform, the stock's price action remains volatile as investors weigh the breakthrough clinical results against concerns about market competition and future reimbursement.

Greenland Energy Co. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2024 and is headquartered in New York, NY.

Greenland Energy Co.

Greenland Energy (GLND) is surging as community sentiment centers on a major drilling partnership with Halliburton for a 2026 campaign in the Jameson Land Basin, which investors view as a pivotal validation of the company's Arctic oil and mineral assets. Discussions are heavily focused on the stock's low float, extreme short interest, and the potential for a significant squeeze amid heightened global interest in energy security.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics Inc.

Oruka Therapeutics is surging following positive interim Phase 2a results for its ORKA-001 trial in plaque psoriasis, which demonstrated strong skin clearance rates and potential for long-term dosing. Investors are actively debating the company's clinical prospects compared to existing market leaders, while also monitoring potential dilution risks from recent capital-raising activities.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences (SGMT) is trending as the market processes the company's strategic decision to prioritize its acne program, including the upcoming initiation of a Phase 3 trial, alongside a successful capital raise of $175 million. The community is actively debating the impact of this significant equity offering on dilution versus the potential validation of the company's long-term commercial runway and accelerated development timeline for denifanstat.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon is trending as investors rotate into defensive, high-dividend yield stocks amid broader market volatility and uncertainty. The stock is attracting significant attention following recent subscriber growth, a major share buyback announcement, and optimism regarding the company's competitive position in wireless and fiber services.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is under intense focus as investors weigh the company's Q4 financial performance against a conservative 2026 outlook and the upcoming TDAPA reimbursement transition. The community is actively debating the company's commercial execution and the potential for a rebound driven by a share buyback program and upcoming Phase 3 trial data.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
